Tags

Type your tag names separated by a space and hit enter

Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
J Am Coll Cardiol 2009; 54(7):585-94JACC

Abstract

Omega-3 polyunsaturated fatty acid (omega-3 PUFA) therapy continues to show great promise in primary and, particularly in secondary prevention of cardiovascular (CV) diseases. The most compelling evidence for CV benefits of omega-3 PUFA comes from 4 controlled trials of nearly 40,000 participants randomized to receive eicosapentaenoic acid (EPA) with or without docosahexaenoic acid (DHA) in studies of patients in primary prevention, after myocardial infarction, and most recently, with heart failure (HF). We discuss the evidence from retrospective epidemiologic studies and from large randomized controlled trials showing the benefits of omega-3 PUFA, specifically EPA and DHA, in primary and secondary CV prevention and provide insight into potential mechanisms of these observed benefits. The target EPA + DHA consumption should be at least 500 mg/day for individuals without underlying overt CV disease and at least 800 to 1,000 mg/day for individuals with known coronary heart disease and HF. Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA omega-3 PUFA that provides maximal cardioprotection in those at risk of CV disease as well in the treatment of atherosclerotic, arrhythmic, and primary myocardial disorders.

Authors+Show Affiliations

Department of Cardiovascular Diseases, Ochsner Medical Center, New Orleans, LA 70121-2483, USA. clavie@ochsner.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19660687

Citation

Lavie, Carl J., et al. "Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases." Journal of the American College of Cardiology, vol. 54, no. 7, 2009, pp. 585-94.
Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7):585-94.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009). Omega-3 polyunsaturated fatty acids and cardiovascular diseases. Journal of the American College of Cardiology, 54(7), pp. 585-94. doi:10.1016/j.jacc.2009.02.084.
Lavie CJ, et al. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. J Am Coll Cardiol. 2009 Aug 11;54(7):585-94. PubMed PMID: 19660687.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 polyunsaturated fatty acids and cardiovascular diseases. AU - Lavie,Carl J, AU - Milani,Richard V, AU - Mehra,Mandeep R, AU - Ventura,Hector O, PY - 2009/02/05/received PY - 2009/02/25/accepted PY - 2009/8/8/entrez PY - 2009/8/8/pubmed PY - 2009/9/1/medline SP - 585 EP - 94 JF - Journal of the American College of Cardiology JO - J. Am. Coll. Cardiol. VL - 54 IS - 7 N2 - Omega-3 polyunsaturated fatty acid (omega-3 PUFA) therapy continues to show great promise in primary and, particularly in secondary prevention of cardiovascular (CV) diseases. The most compelling evidence for CV benefits of omega-3 PUFA comes from 4 controlled trials of nearly 40,000 participants randomized to receive eicosapentaenoic acid (EPA) with or without docosahexaenoic acid (DHA) in studies of patients in primary prevention, after myocardial infarction, and most recently, with heart failure (HF). We discuss the evidence from retrospective epidemiologic studies and from large randomized controlled trials showing the benefits of omega-3 PUFA, specifically EPA and DHA, in primary and secondary CV prevention and provide insight into potential mechanisms of these observed benefits. The target EPA + DHA consumption should be at least 500 mg/day for individuals without underlying overt CV disease and at least 800 to 1,000 mg/day for individuals with known coronary heart disease and HF. Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA omega-3 PUFA that provides maximal cardioprotection in those at risk of CV disease as well in the treatment of atherosclerotic, arrhythmic, and primary myocardial disorders. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/19660687/Omega_3_polyunsaturated_fatty_acids_and_cardiovascular_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(09)01709-4 DB - PRIME DP - Unbound Medicine ER -